Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Jefferies Cuts Opinion on Alkermes


Jefferies cut its opinion on Alkermes(ALKS) to hold from buy.

Analyst David Windley said the Food and Drug Administration extended its deadline for completing the review of Vivitrex NDA by three months, classifying its recent response from Alkermes as a major amendment and thus requiring a longer review period. The analyst says that since the press release does not elaborate on a specific response that led the Food and Drug Administration to classify it as a major amendment, there's low visibility around the timing of the medical treatment's eventual approval and product launch. The analyst had raised his target to $18 in August to reflect the Vivitrex co-promotion deal.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus